Recently, Stefan joined GSK as Global Head Experimental Medicine overseeing translational medicine, biomarkers, companion diagnostics and clinical / translational alliances. He is responsible for strategic and operational aspects of personalized healthcare across Phase 1 to Phase 4.
Prior to joining GSK, Stefan held the position of SVP Clinical Development and CMO in Cellectis, a clinical stage biotech specializing in allogeneic CAR-Ts. In this role he was responsible for setting the medical and clinical development strategy for multiple assets, in addition to building and expanding a clinical team. During his tenure he brought programs in AML and ALL to the clinic and worked to achieve an IND approval for a target in MM.
Previously, Stefan served as Vice President and Head of EDS&I (Early Development, Strategy and Innovation) in Novartis. In this unique role, he led broad teams, both in the medical and commercial functions, that planned and executed oncology studies for early stage compounds, to identify and implementing innovative signal seeking investigator sponsored trials. Prior to this, Stefan served as Vice President, Global Head Correlative Sciences, Translational Precision Oncology where he was responsible for translational activities, biomarker and diagnostics assay development of targeted therapies, immunotherapies and cell-based therapies in both solid tumors and hematology.
Before joining Novartis, Stefan worked at Biocartis as the CMO responsible for the assay development and diagnostic strategy of the company.
For over six years, Stefan held positions of increasing responsibility at F. Hoffmann-La Roche /Genentech, starting as the biomarker program leader for Avastin and soon after overseeing the biomarker work for the angiogenesis franchise. Stefan later served as Global Head Biomarkers and Translational Medicine in Pharma Development overseeing the biomarker, diagnostic, translational medicine in late stage Oncology. During his tenure he worked closely with external partners in academia and commercial entities to established multiple translational hubs to further accelerate scientific discoveries that resulted in the generation of strategic data as well as numerous publications including multiple papers in high impact journals.
Stefan received his M.D. from University of Freiburg and University of Saarbruecken/Homburg Medical School, Germany and his Ph.D. in Biomedical Sciences from the University of Wuerzburg – Biocenter, Wuerzburg, Germany. Stefan earned a post graduate degree in Bioinformatics from the Academy for postgraduate education with the Universities of Heidelberg and Mannheim, Germany.